Prostate cancer

Relationship between CYP17 gene polymorphisms and risk of prostate cancer

J. Song, Tao, Z. - H., Liu, X. - Y., Gong, S., Gan, L., Song, J., Tao, Z. - H., Liu, X. - Y., Gong, S., and Gan, L., Relationship between CYP17 gene polymorphisms and risk of prostate cancer, vol. 15, p. -, 2016.

Cytochrome P450 17a-hydroxylase (CYP17) plays a critical role in androgen biosynthesis. Polymorphisms of the CYP17 promoter have been proposed as risk factors for prostate cancer; however, some studies have produced inconclusive or controversial results. We investigated the relationship between polymorphisms of the CYP17 gene and the risk of prostate cancer. A total of 176 patients with prostate cancer were enrolled in the study, and 168 healthy individuals acted as the control group. The participants were divided into those CYP17 in the samples.

Role of interleukin-6 gene polymorphisms in the development of prostate cancer

C. H. Chen, Gong, M., Yi, Q. T., and Guo, J. H., Role of interleukin-6 gene polymorphisms in the development of prostate cancer, vol. 14, pp. 13370-13374, 2015.

We investigated the role of two functional polymorphisms, IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796), in the development of prostate cancer. A total of 212 consecutive primary prostate cancer patients and 236 control subjects were recruited between May 2012 and May 2014. The IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796) polymorphisms were assessed by polymerase chain reaction-restriction fragment length polymorphism. The genotype distributions of IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796) met the Hardy-Weinberg equilibrium in the controls.

Subscribe to Prostate cancer